Home
 /
Papers
 /
Microbiology
 /
A Protein Antibiotic Inhibits the BAM Complex to Kill Without Cell Entry
Preprint
Open access
V1
Top 1% · Validated by QED

A Protein Antibiotic Inhibits the BAM Complex to Kill Without Cell Entry

Fabian Munder, Matthew Johnson, Imogen Samuels +17 more
September 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.09.18.677229
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Microbiology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that protein antibiotics kill Gram-negative pathogens by trapping the BAM complex at the cell surface—no membrane penetration required—this work overturns a foundational premise in antibiotic discovery and defines an engineerable new therapeutic modality.

QED claims analysis

Summary

L-type pyocins kill Pseudomonas aeruginosa without cell entry by binding BamA loop 6 at the cell surface and deploying a C-terminal peptide that competitively inhibits the BAM complex through β-strand 1 binding, ultimately causing catastrophic outer membrane disruption and cell death despite rapid cellular stress responses.

See full analysis
Main Claim 1 –

L-type pyocins potently inhibit P. aeruginosa at nanomolar IC50

Supporting evidence

  • Multiple L-type pyocins kill diverse P. aeruginosa clinical isolates
  • BamA loop 6 variation correlates with pyocin susceptibility
  • C-terminal peptide is essential for L-type pyocin activity
Main Claim 2 –

Native P. aeruginosa BAM adopts an outward-open conformation

Main Claim 3 –

L-type pyocins bind BamA loop 6 and deploy C-terminus

Main Claim 4 –

L-type pyocins inhibit BAM via β-strand 1 β-augmentation

Supporting evidence

  • C-terminal peptide requires β-lectin attachment for cytotoxicity
  • Pyocin–BAM inhibition proceeds through a two-step conformational transition

Abstract

Many antibiotics are ineffective against Gram-negative pathogens such as Pseudomonas aeruginosa because they cannot penetrate the bacterial outer membrane. Here, we show that protein antibiotics called L-type pyocins kill P. aeruginosa by inhibiting the β-barrel assembly machinery (BAM) complex at the cell surface, halting outer-membrane protein assembly. Using single-particle cryo-electron microscopy, we show that L-type pyocins bind a surface-exposed region of BamA and deploy a C-terminal peptide that competitively inhibits the BAM complex, demonstrating that cell entry is not required for antibiotic activity. We combine genetics, multi-omics and cryo-electron tomography to show that BAM complex inhibition by L-type pyocins or the peptide antibiotic darobactin triggers a multifaceted transcriptomic, proteomic and morphological response. Despite this, BAM inhibition ultimately leads to a catastrophic loss of membrane integrity and cell death. These results validate BAM as a target for antibiotics that do not enter the cell and define an engineerable system for their development.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?